Oramed Pharmaceuticals Inc.
Clinical-stage company developing oral drug delivery for injectable medications.
ORMP | TA
Overview
Corporate Details
- ISIN(s):
- US68403P2039
- LEI:
- Country:
- Israel
- Address:
- 20 Mamilla Avenue, 9414904 Jerusalem
- Website:
- https://www.oramed.com
- Sector:
- Manufacturing
Description
Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-03-19 15:21 |
Update on the receipt of payments for the Scilex transaction
|
English | 109.2 KB | ||
| 2024-03-19 15:21 |
Update on the receipt of payments for the Scilex transaction
|
English | 36.3 KB | ||
| 2024-03-19 00:38 |
Appointed Mr. Yehuda Reznick to serve as a director
|
English | 94.5 KB | ||
| 2024-03-19 00:38 |
Appointed Mr. Yehuda Reznick to serve as a director
|
English | 36.4 KB | ||
| 2024-03-19 00:35 |
entered into ATM Agreemen with Agents having maximum aggregate offering price u…
|
English | 527.5 KB | ||
| 2024-03-19 00:35 |
entered into ATM Agreemen with Agents having maximum aggregate offering price u…
|
English | 36.3 KB | ||
| 2024-03-19 00:33 |
Form 424b5-AT THE MARKET AGREEMENT Up to $75,000,000 COMMON STOCK
|
English | 367.0 KB | ||
| 2024-03-19 00:33 |
Form 424b5-AT THE MARKET AGREEMENT Up to $75,000,000 COMMON STOCK
|
English | 36.3 KB | ||
| 2024-03-07 01:18 |
10K: Annual Report For the Fiscal Year Ended December 31, 2023
|
English | 1.7 MB | ||
| 2024-03-07 01:18 |
10K: Annual Report For the Fiscal Year Ended December 31, 2023
|
English | 36.3 KB | ||
| 2024-02-20 16:54 |
Form 8-K - CEO Letter
|
English | 252.6 KB | ||
| 2024-02-20 16:54 |
Form 8-K - CEO Letter
|
English | 36.4 KB | ||
| 2024-01-31 01:42 |
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Aghion Daniel
|
English | 58.2 KB | ||
| 2024-01-31 01:42 |
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Aghion Daniel
|
English | 36.4 KB | ||
| 2024-01-24 01:16 |
JOINT VENTURE AGREEMENT
|
English | 665.8 KB |
Automate Your Workflow. Get a real-time feed of all Oramed Pharmaceuticals Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oramed Pharmaceuticals Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oramed Pharmaceuticals Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
